Helen Tager-Flusberg is director of the Center for Autism Research Excellence at Boston University. Her research aims to untangle autism and language impairments using behavioral and brain-imagining studies. She was also a columnist for Spectrum.
Helen Tager-Flusberg
Boston University
From this contributor
Why no one needs a diagnosis of ‘social communication disorder’
A diagnosis of social communication disorder only keeps people from a community and resources they desperately want and need.
Why no one needs a diagnosis of ‘social communication disorder’
By
Helen Tager-Flusberg
17 April 2018 | 1 min read
Should scientists study mothers of children with autism?
Studying parents of children with autism has long been controversial, but that doesn’t mean scientists should avoid it.
Should scientists study mothers of children with autism?
By
Helen Tager-Flusberg
12 April 2016 | 1 min read
‘Frozen’ offers glimpse of autism in girls
Elsa, the star of the movie “Frozen,” is the poster child for girls with autism.
‘Frozen’ offers glimpse of autism in girls
By
Helen Tager-Flusberg
15 September 2015 | 4 min read
Time for some soul-searching in science
Scientists should slow down and return to the basic tenets of research to regain the public’s trust.
Time for some soul-searching in science
By
Helen Tager-Flusberg
1 September 2015 | 1 min read
Better behavioral tests may save trials of autism treatments
Trials to test drugs for autism suffer from subjective measurements and placebo effects. Helen Tager-Flusberg outlines how to ferret out the true effects of potential autism therapies.
Better behavioral tests may save trials of autism treatments
By
Helen Tager-Flusberg
21 April 2015 | 1 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read